Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
'Impressive' New Data on Novel Schizophrenia Hopeful KarXT medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
NGN-401 has been generally well-tolerated by first three patients dosed, with three to nine months of follow-up
No signs or symptoms of overexpression toxicity, including in one patient with a mild.